Lakewood-Amedex Biotherapeutics Inc. Common Stock (LABT) — Net Asset Momentum
Lakewood-Amedex Biotherapeutics Inc. Common Stock (LABT) recorded a net asset momentum of -579.6% as of December 2025, with net assets of $-1.96 Million USD. Net Asset Momentum measures the year-over-year percentage change in net assets (total assets minus total liabilities), indicating how rapidly the company is building or eroding its equity base. Check tangible equity quality of Lakewood-Amedex Biotherapeutics Inc. Com to evaluate the tangible quality of the company's equity base.
YoY Momentum
Current Net Assets
Years of Data
Country
Lakewood-Amedex Biotherapeutics Inc. Common Stock Net Asset Momentum (2023–2025)
This chart tracks Lakewood-Amedex Biotherapeutics Inc. Common Stock's year-over-year net asset growth across 3 annual reporting periods from 2023 to 2025. The most recent momentum reading is -579.6%, with net assets of $-1.96 Million USD as of December 2025. See Lakewood-Amedex Biotherapeutics Inc. Com shareholders equity for net asset value and shareholders' equity analysis.
Annual Net Asset History for Lakewood-Amedex Biotherapeutics Inc. Common Stock (2023–2025)
The table below shows the complete annual net asset history for Lakewood-Amedex Biotherapeutics Inc. Common Stock from 2023 to 2025, covering 3 yearly periods. Each row includes total assets, total liabilities, net assets, and the year-over-year momentum figure for that period. For live market cap and overall valuation, see Lakewood-Amedex Biotherapeutics Inc. Com (LABT) total market value.
| Year | Net Assets (USD) | Total Assets | Total Liabilities | YoY Momentum |
|---|---|---|---|---|
| 2025 | $-1.96 Million | $481.60K | $2.45 Million | ▼ -579.6% |
| 2024 | $409.61K | $1.07 Million | $660.97K | ▼ -91.0% |
| 2023 | $4.56 Million | $6.89 Million | $2.34 Million | — |